Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel and gemcitabine with or without VCN-01 in metastatic pancreatic cancer
2022-000897-24Phase 2Terminated
- Sponsor
- Theriva Biologics
- Start
- Jun 2022
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zabilugene almadenorepvec in pancreatic cancer (PDAC) (2 arms), sponsored by Theriva Biologics. Primary endpoint: Overall survival. Started Jun 2022; status: terminated.
02
Drugs
zabilugene almadenorepvec
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2022-000897-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000897-24.